Dit zag ik vanochtend in de newsfeed voorbij komen:
Immunovaccine Announces the Publication of DPX-0907 Preclinical Study
Study shows the DepoVaxTM platform provides a superior immune response against cancer antigens
Als dit geen goed nieuws is, weet ik het ook niet meer 🙂
HALIFAX, NOVA SCOTIA–(Marketwire – April 5, 2010) – Immunovaccine Inc. (TSX VENTURE:IMV), a clinical stage vaccine development company, announced today the publication of data from a preclinical study with its candidate cancer vaccine, DPX-0907, in human class I MHC transgenic mice. The study compares Immunovaccine’s novel DepoVax™ vaccine platform to a vaccine formulation commonly used to deliver peptide antigens in the clinic today. The study shows that the company’s DepoVax™ platform promotes antigen specific immune responses, however, unlike the control vaccine, the DepoVax™ formulation does not induce problematic immune regulatory responses.